1. **Treatment & Condition**
   Ocrelizumab for treating primary progressive multiple sclerosis.

2. **Associated appraisal body & Summary of ruling**
   NICE Technology Appraisal guidance TA585 (June 2019)
   Ocrelizumab (Ocrevus®) is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. It is recommended only if the company provides it according to the commercial arrangement.

3. **Number of people in Northern Ireland expected to take up service/therapy**

<table>
<thead>
<tr>
<th>Estimated number of people in Northern Ireland having ocrelizumab for primary progressive MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population having ocrelizumab each year</td>
</tr>
<tr>
<td>------------------------------------------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

4. **Patient Access Scheme Availability**

   *(Yes/No)*

   The company (Roche) has a commercial arrangement. This makes ocrelizumab available to the NHS with a discount. The size of the discount is commercial in confidence.

5. **Infrastructure Requirements**

   Infrastructure requirements for the delivery of all disease modifying therapies (DMTs) for MS are reviewed annually as part of routine commissioning arrangements for supporting growth in the provision of these therapies.

6. **Expected implementation period**

   There is no impediment to immediate implementation for new patients.

7. **Commissioning arrangements**

   This drug will be formally commissioned by HSCB/PHA via the Specialist Services Commissioning Team initially on a cost per case basis.
8. **Monitoring arrangements**

The HSC Board has robust arrangements in place for the monthly monitoring of all DMTs (patient numbers, costs and waiting times). This regime will be included within the monitoring information.

Monitoring returns are reviewed by the Specialist Services Commissioning Team each month.

---

9. **DoH (NI) Legislative/Policy Caveats**

This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.